

Bcl-6 (0.N.26): sc-70414

BACKGROUND

Bcl-6, a transcriptional repressor, binds Stat recognition-like DNA elements and influences germinal center development and Th1/Th2 differentiation. Bcl-6 negatively regulates NFκB expression, thereby inhibiting NFκB-mediated cellular functions. HDAC- and silent information regulator (SIR)-2-dependent acetylation of Bcl-6 causes downregulation of activity by inhibiting the ability of Bcl-6 to recruit complexes containing histone deacetylases (HDAC). Bcl-6 is frequently deregulated in non-Hodgkin's B cell lymphomas. The human Bcl6 gene has been shown to encode a protein of 706 amino acids.

REFERENCES

1. Pasqualucci, L., et al. 2003. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. *Leuk. Lymphoma* 44: S5-S12.
2. Ree, H.J., et al. 2003. Detection of germinal center B cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. *Hum. Pathol.* 34: 610-616.
3. Logarajah, S., et al. 2003. Bcl-6 is expressed in breast cancer and prevents mammary epithelial differentiation. *Oncogene* 22: 5572-5578.
4. Bos, R., et al. 2003. Protein expression of B-cell lymphoma gene 6 (Bcl6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1α (HIF-1α). *Oncogene* 22: 8948-8951.
5. Kurosu, K., et al. 2004. Bcl-6 mutations in pulmonary lymphoproliferative disorders: demonstration of an aberrant immunological reaction in HIV-related lymphoid interstitial pneumonia. *J. Immunol.* 172: 7116-7122.
6. Tunyaplin, C., et al. 2004. Direct repression of PRDM1 by Bcl-6 inhibits plasmacytic differentiation. *J. Immunol.* 173: 1158-1165.
7. Ozaki, K., et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. *J. Immunol.* 173: 5361-5371.

CHROMOSOMAL LOCATION

Genetic locus: BCL6 (human) mapping to 3q27.3; Bcl6 (mouse) mapping to 16 B1.

SOURCE

Bcl-6 (0.N.26) is a mouse monoclonal antibody raised against amino acids 3-484 of Bcl-6 of human origin.

PRODUCT

Each vial contains 250 µl culture supernatant containing IgG₁ with < 0.1% sodium azide.

STORAGE

For immediate and continuous use, store at 4° C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

APPLICATIONS


Bcl-6 (0.N.26) is recommended for detection of Bcl-6 of mouse, rat and human origin by Western Blotting (starting dilution to be determined by researcher, dilution range 1:10-1:200), immunoprecipitation [1-2 µl per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution to be determined by researcher, dilution range 1:10-1:200) and immunohistochemistry (including paraffin-embedded sections) (starting dilution to be determined by researcher, dilution range 1:10-1:200).

Suitable for use as control antibody for Bcl-6 siRNA (h): sc-29791, Bcl-6 siRNA (m): sc-29792, Bcl-6 shRNA Plasmid (h): sc-29791-SH, Bcl-6 shRNA Plasmid (m): sc-29792-SH, Bcl-6 shRNA (h) Lentiviral Particles: sc-29791-V and Bcl-6 shRNA (m) Lentiviral Particles: sc-29792-V.

Molecular Weight of Bcl-6: 95 kDa.

Positive Controls: Ramos cell lysate: sc-2216, Raji whole cell lysate: sc-364236 or BJAB whole cell lysate: sc-2207.

DATA




Bcl-6 (0.N.26): sc-70414. Western blot analysis of Bcl-6 expression in Ramos (A), Raji (B), U-698-M (C) and BJAB (D) whole cell lysates.

SELECT PRODUCT CITATIONS

1. Iempridee, T., et al. 2014. Epstein-Barr virus utilizes Ikaros in regulating its latent switch in B cells. *J. Virol.* 88: 4811-4827.
2. Kerres, N., et al. 2017. Chemically induced degradation of the oncogenic transcription factor Bcl6. *Cell Rep.* 20: 2860-2875.
3. Wille, C.K., et al. 2017. Restricted TET2 expression in germinal center type B cells promotes stringent Epstein-Barr virus latency. *J. Virol.* 91: e01987-16.
4. Perfecto-Avalos, Y., et al. 2019. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. *J. Transl. Med.* 17: 198.

RESEARCH USE

For research use only, not for use in diagnostic procedures.



See **Bcl-6 (D-8): sc-7388** for Bcl-6 antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor® 488, 546, 594, 647, 680 and 790.